24/7 Market News Snapshot 05 June, 2025 – Ocugen, Inc. Common Stock (NASDAQ:OCGN)

June 5, 2025

DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (NASDAQ:OCGN) are discussed in this article.
Ocugen, Inc. (OCGN), a pioneering biotechnology firm committed to addressing significant medical challenges through gene therapies, has been experiencing a notable rally in its stock, currently trading at $0.994, up approximately 12.04% from the prior close of $0.887. The heightened trading activity, with volumes reaching 7.95 million shares, indicates strong investor interest, which may continue to drive volatility. Observations suggest that support is positioned around the $0.90 mark, while the $1.00 threshold presents immediate resistance. Traders are advised to monitor potential breakout patterns, as sustained activity could signal further positive movement in the coming sessions.

In a pivotal development, Ocugen has entered into a strategic partnership with a notable pharmaceutical entity, aimed at advancing its innovative gene therapy, OCU400, for the treatment of retinitis pigmentosa (RP). The recently established binding term sheet grants exclusive rights to OCU400 within a designated territory, which has the potential to significantly expand patient access to this promising therapy.

The agreement outlines various financial benefits for Ocugen, including upfront licensing fees and up to $11 million in developmental milestone payments. Key sales milestones have been articulated, with provisions directing $1 million in payments for every $15 million in net sales, complemented by a robust 25% royalty on net sales attributed to OCU400. Ocugen will also maintain responsibilities for manufacturing and the commercial supply of the product.

Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, underscored the strategic alignment of this partnership with the company’s mission, emphasizing their goal to partner with established organizations to efficiently treat RP patients while ensuring shareholder value. With OCU400 progressing through Phase 3 clinical trials, Ocugen is poised to submit a Biologics License Application by mid-2026, promising to enhance therapeutic options for patients affected by this debilitating condition. Further updates regarding the licensing agreement will be revealed in the months ahead.

Related news for (OCGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.